Description SS31 (Elamipretide) [Peptide] The product is intended for laboratory research only and not for human consumption. Available quantities: 10 mg Product Information PubChem CID 11764719 Peptide purity (HPLC) 98-99% CAS 736992-21-5 Molar mass 639.8 g/mol Chemical formula C32H49N9O5 Synonyms Elamipretide IUPAC Arg-Dmt-Lys-Phe-NH₂ Source Synthetic Form Powder Shelf Life 12–14 months under recommended conditions Molecular Sequence of SS31 Elamipretide Peptide D-Arg–Dmt–Lys–Phe–NH₂ Dmt: 2′,6′-Dimethyltyrosine D-Arg: D-Arginine (D-enantiomer form) C-terminal: Amidated (–NH₂) Recommended Handling and Storage The compound should be stored in a cool and dry place to maximize its stability. For better storage, it is recommended to keep the SS31 lyophilized peptide refrigerated between 2°C and 8°C (36°F–46°F) in an airtight container. Overview of Elamipretide Peptide SS31 is a water-soluble tetrapeptide, a synthetic peptide also known as Elamipretide, which shows selective binding to cardiolipin. Cardiolipin is a phospholipid highly enriched in the inner mitochondrial membrane in experimental models. Mechanism of Action in Research Models Preclinical studies suggest that Elamipretide is designed to protect and repair mitochondria, the energy-producing structures inside cells. It mainly works through binding to cardiolipin, a phospholipid enriched in the inner mitochondrial membrane. Studies indicate that Elamipretide contains two positively charged amino acids, D-Arg and Lys. This enables it to target the inner mitochondrial membrane, which is highly negatively charged. Preclinical studies indicate that it may have effects on stabilising mitochondrial structure and respiration. Preclinical data demonstrate the potential of the peptide SS31 (Elamipretide) to improve electron transport chain function and ATP production in laboratory models. Elamipretide is being studied for several mitochondrial-related conditions, such as: Heart failure and cardiomyopathy in laboratory models Mitochondrial myopathies in research models Age-related macular degeneration in analytical models Elamipretide is provided in its TFA salt form. Residual trifluoroacetate content is typically up to 10% w/w. It depends on the final formulation and lyophilization conditions. The exact TFA content can be confirmed by batch-specific COA. Disclaimer Elamipretide peptide is intended exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has not evaluated the statements on our website. By purchasing, you agree to our Terms and Conditions.
